Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer
Overview
Authors
Affiliations
Background: The diagnosis of malignant diseases worldwide has been determined using F-fluorodeoxyglucose positron emission tomography (FDG-PET). Glucose transporter type 1 (Glut-1) is a key protein associated with the accumulation of FDG in cancer cells. This study evaluated the relationship between Glut-1 expression and FDG accumulation to determine the usefulness of FDG-PET for prediction of long-term outcomes of pancreatic cancer.
Methods: The expression of Glut-1 was immunohistochemically examined in 138 surgically resected pancreatic cancer specimens. The Glut-1-positive and Glut-1-negative groups were analyzed with respect to their clinicopathologic characteristics and prognosis. Before surgery, 93 patients underwent FDG-PET and measurement of the corrected maximum standardized uptake value (cSUVmax). The relationship between Glut-1 expression and cSUVmax were examined, and prognostic factors were identified using uni- and multivariate analyses.
Results: Glut-1 was positive in 69 patients (50%). The median relapse-free and overall survival times were significantly shorter in the Glut-1-positive group (11 vs. 22 months, respectively) than in the Glut-1-negative group (23 vs. 42 months, respectively). The cSUVmax was significantly associated with long-term survival. The relapse-free and overall survival rates were significantly poorer in the high-cSUVmax group than in the low-cSUVmax group. Glut-1 expression was associated with cSUVmax accumulation. In the multivariate Cox regression analysis using forward stepwise selection, male gender, positive lymph node metastases, high CA19-9, and high cSUVmax were identified as independent prognostic factors for pancreatic cancer.
Conclusion: A significant relationship exists between high preoperative cSUVmax and Glut-1 expression. High cSUVmax is one of the prognostic factors for overall survival after resection of pancreatic cancer.
Huang Y, Zhang H, Ding Q, Chen D, Zhang X, Weng S Front Oncol. 2024; 14:1419297.
PMID: 39605884 PMC: 11598923. DOI: 10.3389/fonc.2024.1419297.
Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W Eur J Nucl Med Mol Imaging. 2023; 50(6):1780-1791.
PMID: 36695823 DOI: 10.1007/s00259-022-06100-4.
Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma.
Liu Z, Hayashi H, Matsumura K, Uemura N, Shiraishi Y, Sato H Cancers (Basel). 2023; 15(2).
PMID: 36672448 PMC: 9856866. DOI: 10.3390/cancers15020498.
Liu Z, Hayashi H, Matsumura K, Ogata Y, Sato H, Shiraishi Y Br J Cancer. 2022; 128(5):844-856.
PMID: 36536047 PMC: 9977781. DOI: 10.1038/s41416-022-02106-9.
Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis.
Wang C, Xu R, Song J, Chen Y, Yin X, Ruze R Front Oncol. 2022; 12:1004850.
PMID: 36172154 PMC: 9510923. DOI: 10.3389/fonc.2022.1004850.